Literature DB >> 12027592

Cardiovascular effects of romifidine in the standing horse.

S L Freeman1, I M Bowen, R Bettschart-Wolfensberger, H I K Alibhai, G C W England.   

Abstract

The cardiovascular effects of romifidine, an alpha-2 adrenoreceptor agonist, were investigated in six horses using two doses (80 and 120 microg kg(-1)) in a cross-over study design. Cardiac index and mixed venous oxygenation were significantly decreased at 15 and 30 minutes after both doses of romifidine. Systemic vascular resistance was significantly increased with romifidine (120 microg kg(-1)). Arterial blood pressure increased initially and then gradually decreased; the doses of decrease was significant at 90 and 120 minutes with romifidine 80 and 120 microg kg(-1). There were minimal differences between the two doses of romifidine, and both should be used with care especially in horses with cardiovascular compromise, or when used in combination with other cardiovascular depressant drugs. Copyright 2002 Published by Elsevier Science Ltd.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12027592     DOI: 10.1053/rvsc.2001.0533

Source DB:  PubMed          Journal:  Res Vet Sci        ISSN: 0034-5288            Impact factor:   2.534


  3 in total

1.  The use of alpha-2 agonists in the equine practice: comparison between three molecules.

Authors:  S Nannarone; R Gialletti; I Veschini; A Bufalari; F Moriconi
Journal:  Vet Res Commun       Date:  2007-08       Impact factor: 2.459

2.  Dissociative anaesthesia during field and hospital conditions for castration of colts.

Authors:  S Marntell; G Nyman; P Funkquist
Journal:  Acta Vet Scand       Date:  2006       Impact factor: 1.695

3.  Pharmacokinetic profile and partitioning in red blood cells of romifidine after single intravenous administration in the horse.

Authors:  Noemi Romagnoli; Khaled M Al-Qudah; Sara Armorini; Carlotta Lambertini; Anna Zaghini; Alessandro Spadari; Paola Roncada
Journal:  Vet Med Sci       Date:  2017-07-20
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.